ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Reinert T, Ramalho S, de Vasconcelos VCA, Silva LR, da Silva AER, de Andrade CA, Kraft MBPL, Coelho GP, Mandelli J, Binotto M, Cabello C, de Paiva Silva GR, Bines J, Barrios CH, Ellis MJ, Graudenz MS.
Reinert T, et al. Among authors: mandelli j.
Front Oncol. 2020 Apr 3;10:342. doi: 10.3389/fonc.2020.00342. eCollection 2020.
Front Oncol. 2020.
PMID: 32309212
Free PMC article.